NEW MR PARAMETERS TO ASSESS AND MONITOR TENDON XANTHOMAS
James F Griffith1, Teresa M Hu2, David KW Yeung1, D F Wang1, Fan Xiao1, and Brian Tomlinson2

1Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong, 2Medicine, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong

Synopsis

Achilles tendon xanthoma is a key clinical indicator of familial hypercholesteraemia (FH) and associated cardiovascular disease. Treatment that reduces the size of tendon xanthoma also benefits the arterial manifestations of FH. Ultrasound and MRI are often used to detect and monitor treatment response of tendon xanthomas using parameters such as tendon thickness, width and cross-sectional area. However, MR-based parameters derived from the DIXON technique to determine tendon volume and intratendinous percentage fat fraction may be more sensitive than traditional US and conventional MRI.

Objective

Achilles tendon xanthoma is a key clinical indicator of familial hypercholesteraemia (FH) and associated cardiovascular disease. Treatment that reduces the size of tendon xanthoma also benefits the arterial manifestations of FH. Ultrasound (US) and MRI are used to detect and monitor treatment response of tendon xanthomas using parameters such as tendon thickness, width and cross-sectional area (CSA) [1]. MR-based parameters such as tendon volume and intratendinous percentage fat fraction (Dixon technique) may be more sensitive to change than these traditional US and conventional MRI. We compared US and new MR parameters in assessing tendon xanthoma at baseline and following treatment.

Methods

After ethical approval was obtained, US (thickness, width, CSA) and MRI (thickness, width, CSA, volume and fat/water fraction) of the Achilles tendons in 19 FH patients with clinical tendon xanthomas was performed at baseline and compared to 10 normocholesterolaemic patients. MR imaging was performed at 3T (Achieva TX, Philips Medical Systems, Best, the Netherlands) using a 16-channel torso array coil for signal reception. Both legs were examined while lying in the supine, feet-first position. T1-weighted axial images were obtained along the length of the Achilles tendon (TR 653ms; TE 20ms; FOV 300mm; NSA 1; slice thickness 4mm; gap 0.4mm; matrix size 547 × 1200). Fat-water images were acquired using a multiecho 3D gradient echo sequence (TR 13 ms; first TE 1.2 ms; echo spacing 1 ms; flip angle 3o; FOV 300 mm; slice thickness 3 mm; NEX 4). A relatively short flip angle was employed to minimize T1-related bias between water and fat. FH patients had follow-up US and MR assessment at 3 and 6 months following treatment with probucol, a lipid lowering agent [2].

Results

At baseline, all US and MR parameters were significantly increased in FH patients compared to controls (p< 0.05) (Tables 1a,b). At 6 months, only the newer MR-based parameters, namely relative water and fat fraction and relative fat-volume product, relative water volume fraction showed significant change with treatment (p< 0.05 for all) (Tables 2a,b).

Conclusion

This is the first study to use MR tendon volume and relative fat/water tendon fraction to gauge and monitor tendon xanthomas. These new parameters seem more sensitive than US or traditional MR-based parameters at detecting interval change. This study helps to confirm earlier suggestion that most of the tendon swelling in FH is due to increased tendon water rather than fat deposition [3].

Acknowledgements

The work described in this paper was fully supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. SEG CUHK_02).

References

1. Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest. 2005;35(4):236-44.

2. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23.

3. Abate M, Schiavone C, Salini V, Andia I. Occurrence of tendon pathologies in metabolic disorders. Rheumatology (Oxford). 201;52(4):599-608.

Figures

Table 1a: Comparison of ultrasound Achilles tendon parameters between controls and FH patients at baseline.

Table 1b: Comparison of MR Achilles tendon parameters between controls and FH patients at baseline.

Table 2a: Change in US-based Achilles tendon parameters in FH patients between baseline and following 6 months of Probucol treatment.

Table 2b: Change in MR-based Achilles tendon parameters in FH patients between baseline and following 6 months of Probucol treatment.



Proc. Intl. Soc. Mag. Reson. Med. 24 (2016)
2268